Citius Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CTXR Nasdaq 2834 citiuspharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ - Feb 13th, 2026 6:00 am
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ - Feb 13th, 2026 6:00 am
Citius Oncology and Uniphar sign European distribution deal for Lymphir - Feb 12th, 2026 4:55 am
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar - Feb 11th, 2026 6:00 am
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - Dec 23rd, 2025 2:30 pm
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - Dec 23rd, 2025 2:30 pm
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - Dec 10th, 2025 2:30 pm
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - Dec 9th, 2025 6:30 am
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim - Dec 4th, 2025 6:37 am
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) - Dec 1st, 2025 10:00 am
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting - Nov 25th, 2025 6:00 am
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration - Nov 21st, 2025 6:37 am
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Is Expected To Breakeven In The Near Future - Nov 12th, 2025 9:21 am
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules - Oct 21st, 2025 2:30 pm
Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules - Oct 21st, 2025 6:00 am
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch - Oct 20th, 2025 6:37 am
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences - Oct 17th, 2025 3:00 pm
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™ - Oct 16th, 2025 6:47 am
Citius Oncology, Inc. (NASDAQ:CTOR) stock most popular amongst public companies who own 79%, while individual investors hold 14% - Sep 26th, 2025 5:29 am
Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement - Sep 10th, 2025 2:30 pm